---
title: The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain
  (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/beta-catenin
  signaling
date: '2024-03-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38438856/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240305170533&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer
  with poor survival across a broad range of molecular subtypes. Development of efficacious
  and well-tolerable therapies encompassing the range of mutations that can arise
  in AML remains an unmet need. The bromo- and extra-terminal domain (BET) family
  of proteins represents an attractive therapeutic target in AML due to their crucial
  roles in many cellular functions, regardless of any specific mutation. Many BET
  ...
disable_comments: true
---
Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival across a broad range of molecular subtypes. Development of efficacious and well-tolerable therapies encompassing the range of mutations that can arise in AML remains an unmet need. The bromo- and extra-terminal domain (BET) family of proteins represents an attractive therapeutic target in AML due to their crucial roles in many cellular functions, regardless of any specific mutation. Many BET ...